Bronchitol available to named patients
Tuesday, 17 June, 2008
Pharmaxis (ASX: PXS) will soon be distributing its Bronchitol drug on a named patient basis through UK company IDIS.
Under the arrangement doctors can - through IDIS - prescribe Bronchitol to patients not currently undergoing clinical trials of the drug.
Patients who participate in a named patient program are warned that a drug may have unexpected side-effects, and their doctors are generally indemnified from liability as a result of this disclaimer.
The programs are generally used to allow patients with chronic illnesses access to drugs which can potentially help even in countries where the drug has not yet been cleared for sale. It is particularly used in cases where there is no satisfactory alternative available.
Bronchitol is an inhalant spray aimed at cystic fibrosis and bronchiectasis.
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
